Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.

Shore, Neal D

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. [electronic resource] - The Lancet. Oncology Feb 2016 - 153-163 p. digital

Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1474-5488

10.1016/S1470-2045(15)00518-5 doi


Aged
Aged, 80 and over
Anemia--chemically induced
Anilides--adverse effects
Arthralgia--chemically induced
Back Pain--chemically induced
Benzamides
Constipation--chemically induced
Disease Progression
Disease-Free Survival
Double-Blind Method
Dyspnea--chemically induced
Fatigue--chemically induced
Fractures, Spontaneous--chemically induced
Heart Failure--chemically induced
Hot Flashes--chemically induced
Humans
Hydronephrosis--chemically induced
Hypertension--chemically induced
Male
Middle Aged
Myocardial Infarction--chemically induced
Nausea--chemically induced
Nitriles--adverse effects
Patient Dropouts
Phenylthiohydantoin--adverse effects
Prostatic Neoplasms, Castration-Resistant--drug therapy
Tosyl Compounds--adverse effects